- Home
- ACAD vs NE Comparison
ACAD vs NE Comparison
Compare ACAD & NE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- NE
- Stock Information
- Founded
- ACAD 1993
- NE 1985
- Country
- ACAD United States
- NE United States
- Employees
- ACAD N/A
- NE N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- NE Other Specialty Stores
- Sector
- ACAD Health Care
- NE Consumer Discretionary
- Exchange
- ACAD Nasdaq
- NE Nasdaq
- Market Cap
- ACAD 4.3B
- NE 3.5B
- IPO Year
- ACAD 2004
- NE N/A
- Fundamental
- Price
- ACAD $24.67
- NE $30.58
- Analyst Decision
- ACAD Buy
- NE Buy
- Analyst Count
- ACAD 21
- NE 8
- Target Price
- ACAD $29.30
- NE $33.14
- AVG Volume (30 Days)
- ACAD 1.8M
- NE 2.1M
- Earning Date
- ACAD 11-05-2025
- NE 11-04-2025
- Dividend Yield
- ACAD N/A
- NE 6.51%
- EPS Growth
- ACAD 615.00
- NE N/A
- EPS
- ACAD 1.33
- NE 1.94
- Revenue
- ACAD $1,018,885,000.00
- NE $3,290,137,000.00
- Revenue This Year
- ACAD $14.01
- NE $15.25
- Revenue Next Year
- ACAD $11.72
- NE N/A
- P/E Ratio
- ACAD $18.55
- NE $15.85
- Revenue Growth
- ACAD 14.41
- NE 28.85
- 52 Week Low
- ACAD $13.40
- NE $17.40
- 52 Week High
- ACAD $26.65
- NE $37.99
- Technical
- Relative Strength Index (RSI)
- ACAD 49.69
- NE 65.83
- Support Level
- ACAD $23.34
- NE $29.70
- Resistance Level
- ACAD $25.90
- NE $30.75
- Average True Range (ATR)
- ACAD 0.78
- NE 0.95
- MACD
- ACAD -0.28
- NE 0.21
- Stochastic Oscillator
- ACAD 40.18
- NE 81.85
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About NE Noble Corporation plc A
Noble Corp PLC is an offshore drilling contractor for the oil and gas industry that provides contract drilling services to the international oil and gas industry with its fleet of mobile offshore drilling units. The company focuses on a high-specification fleet of floating and jackup rigs and the deployment of its drilling rigs in oil and gas basins around the world.